Founded in 2000, Bio-Cancer Treatment is currently conducting phase I clinical trials in the US for their product candidate BCT-100, which is aimed at treating solid cancers, and phase II clinical trials in Hong Kong for the treatment of acute myeloid leukemia. Their portfolio also includes BCT-200, a modified version of BCT-100 that is still in the pre-IND stage. The company's patented drugs are arginine depleting agents that slow down tumor growth, offering safe and effective treatment options for multiple cancer indications and autoimmune disorders.